This upgrade follows NovoCure's announcement of a 22% increase in net revenues for the third quarter. NovoCure has also received FDA approval for its Head Flexible Electrode arrays, which are expected ...

Novocure to present at the 43 rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 BAAR, Switzerland, January 13, 2025--(BUSINESS WIRE)--Novocure (NASDAQ ...

NovoCure (NVCR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and ...

Novocure (NASDAQ:NVCR) has reported preliminary revenues of $605.2M for 2024, higher than the consensus estimate of $596.95M. For the fourth quarter, the oncology company issued preliminary ...

In the latest quarter, 7 analysts provided ratings for NovoCure (NASDAQ:NVCR), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings ...

Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and ...